2022年 第13卷 第6期
《工程（英文）》 >> 2022年 第13卷 第6期 doi: 10.1016/j.eng.2021.06.012
糖基工程毕赤酵母制备的SARS-CoV-2 S蛋白RBD受体结合区亚单位疫苗可激发中和抗体反应
a Department of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China
b Medical Innovation Research Division & Fourth Medical Center of the Chinese PLA General Hospital, Beijing 100853, China
c Department of Neurosurgery, First Medical Center of the Chinese PLA General Hospital, Beijing 100853, China
d Shenzhen Taihe Biotechnology Co. Ltd., Shenzhen 518001, China
e Institute of Physical Science and Information Technology, Anhui University, Hefei 230000, China
# These authors contributed equally to this work.
下一篇 上一篇
摘要
2020年至今，新型冠状病毒SARS-CoV-2已经在全球大流行。新冠疫苗被寄于厚望用以减轻防控压力，成为解决疫情危机的有效手段之一。SARS-CoV-2通过S蛋白受体结合区RBD与宿主细胞ACE2受体结合侵染机体。本文提供了一种利用新型糖基工程毕赤酵母表达系统，制备基于S蛋白RBD重组亚单位候选疫苗的方法。该糖基工程酵母的糖基化修饰途径经过人源化改造后，具有类似于哺乳动物细胞糖基化修饰特点。研究发现，RBD候选疫苗可以有效地诱导小鼠产生高滴度的抗RBD特异性抗体，含Al(OH)3和CpG双佐剂的RBD免疫组小鼠产生的特异性抗体滴度和病毒中和抗体滴度显著地高于Al(OH)3单佐剂组，且中和抗体可以在小鼠体内持续6个月以上。综上所述，本文利用糖基工程酵母制备了SARS-CoV-2 S蛋白RBD糖蛋白疫苗，该疫苗能够诱导小鼠产生高滴度中和抗体，同时提供了一种可制备具有无岩藻糖的复杂型N-糖基化修饰重组蛋白的方法。
关键词
冠状病毒 ; SARS-CoV-2 ; 疫苗 ; 酵母 ; 受体结合区（RBD）
图片
图1
图2
图3
图4
图5
图6
参考文献
[ 1 ] www.who.int [Internet]. Geneva: World Health Organization; 2020 [cited2021 Jan 25]. Available from: https://covid19.who.int/region/euro/country/tj. 链接1
[ 2 ] Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020;581(7807):215‒20. 链接1
[ 3 ] Barnes CO, Jette CA, Abernathy ME, Dam KM, Esswein SR, Gristick HB, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 2020;588(7839):682‒7. 链接1
[ 4 ] Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 2020;182(3):722‒33.e11. 链接1
[ 5 ] Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 2020;586(7830):572‒7. 链接1
[ 6 ] Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science 2020;369(6501):330‒3. 链接1
[ 7 ] Cereghino JL, Cregg JM. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol Rev 2000;24(1):45‒66. 链接1
[ 8 ] Dean N. Asparagine-linked glycosylation in the yeast Golgi. Biochim Biophys Acta 1999;1426(2):309‒22. 链接1
[ 9 ] Wildt S, Gerngross TU. The humanization of N-glycosylation pathways in yeast. Nat Rev Microbiol 2005;3(2):119‒28. 链接1
[10] Hamilton SR, Gerngross TU. Glycosylation engineering in yeast: the advent of fully humanized yeast. Curr Opin Biotechnol 2007;18(5):387‒92. 链接1
[11] Liu Bo, Shi P, Wang T, Zhao Y, Lu S, Li X, et al. Recombinant H7 hemagglutinin expressed in glycoengineered Pichia pastoris forms nanoparticles that protect mice from challenge with H7N9 influenza virus. Vaccine 2020;38(50):7938‒48. 链接1
[12] Thomson E, Rosen L, Shepherd J, Spreafico R, Filipe A, Wojcechowskyj J, et al. The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity. Cell 2021;184(5):1171‒87.
[13] HogenEsch H, O’Hagan DT, Fox CB. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines 2018;3(1):51. 链接1
[14] Shivahare R, Vishwakarma P, Parmar N, Yadav PK, Haq W, Srivastava M, et al. Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis. PLoS ONE 2014;9(4):e94596. 链接1
[15] Pulendran B, Arunachalam PS., O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov 2021;20(6):454‒75. 链接1
[16] Choi B-K, Bobrowicz P, Davidson RC, Hamilton SR, Kung DH, Li H, et al. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. Proc Natl Acad Sci USA 2003;100(9):5022‒7. 链接1
[17] Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 2006;24 (2):210‒5. 链接1
[18] Callewaert N, Laroy W, Cadirgi H, Geysens S, Saelens X, Min Jou W, et al. Use of HDEL-tagged Trichoderma reesei mannosyl oligosaccharide 1,2-a-Dmannosidase for N-glycan engineering in Pichia pastoris. FEBS Lett 2001;503(2‒3):173‒8.
[19] Gstöttner C, Zhang T, Resemann A, Ruben S, Pengelley S, Suckau D, et al. Structural and functional characterization of SARS-CoV-2 RBD domains produced in mammalian cells. Anal Chem 2021;93(17):6839‒47. 链接1
[20] Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MAL, Krieg AM, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004;24(6):693‒701. 链接1
[21] Zhou D, Tian X, Qi R, Peng C, Zhang W. Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: implications for vaccination and antibody therapeutics. Glycobiology 2021;31(1):69‒80.
[22] Yang YL, Chang SH, Gong X, Wu J, Liu B. Expression, purification and characterization of low-glycosylation influenza neuraminidase in a-1,6-mannosyltransferase defective Pichia pastoris. Mol Biol Rep 2012;39(2):857‒64. 链接1
京公网安备 11010502051620号
